KR102199186B1 - A veterinary composition for the prevention and treatment of diseases caused by pathogenic bacteria - Google Patents

Abstract

Disclosed is a veterinary composition capable of preventing and treating diseases caused by pathogenic bacteria, thereby preventing a decrease in the productivity of livestock. The present invention provides a veterinary composition for the prevention and treatment of diseases caused by pathogenic bacteria, comprising florfenicol and acetylsalicylic acid as active ingredients.

Description

A veterinary composition for the prevention and treatment of diseases caused by pathogenic bacteria}

The present invention relates to a veterinary composition, and more particularly, to a veterinary composition for the prevention and treatment of diseases caused by pathogenic bacteria.

Porcine respiratory disease complex (PRDC) mainly occurs in piglets and finishing pigs, and is characterized by poor growth, decreased feed efficiency, lethargy, loss of appetite, fever, cough, and respiratory problems.

Swine respiratory complex infectious diseases are Actinobacilus pleurpneumoniae , Bordetella bronchiseptica ( Bordetella). bronchiseptica ), Pasteurella Multocida , and other mixed infections.

Actinobacilus pluropneumoniae ( Actinobacilus pleurpneumoniae ) is a causative agent of porcine pleural pneumonia with acute and chronic course, and is accompanied by fibrotic pleurisy and hemorrhagic necrotizing lesions. Respiratory diseases caused by this fungus are common in poor environments or in dense breeding conditions, and pigs infected with this disease cause growth delays including mortality and decrease in feed efficiency, which causes a lot of economic loss to the pig farming industry.

Pasteurella multocida Multocida ) is a pathogen that causes respiratory disease in pigs as well as a fungal organism in the respiratory tract, and is classified into types A, B, D, E and F according to the serotype of the capsular membrane as Gram-negative bacteria. The toxicity is determined by the presence of the toxA gene, which encodes a 145kDa toxic protein, and it tends to appear mainly in A or D type. Type A is known to cause bronchial pneumonia in pigs, cattle and chickens, and type D is known to cause atrophic rhinitis (AR) in pigs.

Bordetella Chevron kisep Utica (Bordetella bronchiseptica ) is a fungus that causes porcine atrophic rhinitis (AR) as a fungus of the porcine nasal mucosa, and symptoms of sneezing, runny nose increase, nasal congestion, dyspnea and growth sluggishness appear when swine atrophic rhinitis occurs. . After an inflammatory runny nose, nasal bleeding is also observed.

Patent No. 1776274 relates to an antibiotic for animals using florfenicol, and describes antibiotics that can be used as injections, but does not describe the prevention and treatment of bacterial diseases using florfenicol.

Accordingly, the present invention has been conceived to solve the above problem, and is to provide a veterinary composition capable of preventing and treating diseases caused by pathogenic bacteria, thereby preventing a decrease in productivity of livestock.

In order to solve the above problems, the present invention provides a veterinary composition for the prevention and treatment of diseases caused by pathogenic bacteria, including florfenicol and acetylsalicylic acid as active ingredients.

In addition, it provides a veterinary composition, characterized in that the content ratio of the florfenicol and acetylsalicylic acid is 1:2 ~ 1:10.

In addition, the pathogenic bacteria are Actinobacillus pleuropneumoniae , Pasteurella multocida ( Pasteurella Multocida ) Type A, Pasteurella Multocida ) D-type or Bordetella bronchiseptica ( Bordetella bronchiseptica ) It provides a veterinary composition, characterized in that.

In addition, the veterinary composition provides a veterinary composition comprising vitamin C (Ascorbic Acid) and ferrous sulfate heptahydrate (FeSO4·7H2O).

In addition, the veterinary composition provides a veterinary composition for the prevention and treatment of bacterial diseases, characterized in that 0.005 to 2% by weight of the total composition content for livestock feed.

The present invention can provide a veterinary composition capable of preventing and treating diseases caused by pathogenic bacteria by mixing a specific compound in a veterinary composition, and preventing a decrease in productivity of livestock.

1 is a graph showing the results of measuring changes in clinical symptoms after challenge vaccination.
Figure 2 is a graph showing the results of measuring the average daily weight gain until 14 days after the challenge vaccination,
3 is a graph showing the results of measuring the number of bacteria of Pasteurella multocida per tissue,
4 is a graph showing the results of measuring the number of bacteria of Bordetella bronchiseptica per tissue,
5 is a photograph of the lungs of the control group for pathological examination,
6 is a photograph of the lungs of a control group showing symptoms of pandemic pneumonia for pathological examination,
7 is a photograph of the lungs of the treatment group for pathological examination,
Figure 8 is a graph showing the results of measuring the pneumoconiosis index of the control group and the treatment group after challenge vaccination,
9 is a photograph taken to measure the degree of loss of the septum and turbinate of the control group and the treatment group,
10 is a graph showing the results of measuring the atrophic rhinitis index of the control group and the treatment group.

Hereinafter, a preferred embodiment of the present invention will be described in detail. In describing the present invention, when it is determined that a detailed description of a related known technology may obscure the subject matter of the present invention, a detailed description thereof will be omitted. Throughout the specification, when a part "includes" a certain component, it means that other components may be further included rather than excluding other components, unless otherwise stated.

The present inventors in the veterinary composition for the prevention and treatment of diseases caused by pathogenic bacteria, Actinobacillus fluro pneumoniae ( Actinobacilus pleurpneumoniae), Bordetella Chevron kisep Utica (Bordetella Faced with the fact that respiratory diseases caused by bronchiseptica ) and Pasteurella Multocida significantly lower the commodity value of livestock and cause a decrease in productivity, resulting in delays in shipment, causing enormous economic losses to livestock farmers, As a result of repeated intensive research in order to solve this problem, it was discovered that when a veterinary composition was prepared by mixing a specific substance with florfenicol, it was possible to prevent and treat respiratory diseases caused by pathogenic bacteria. Came to pass.

Accordingly, the present invention discloses a veterinary composition for the prevention and treatment of diseases caused by pathogenic bacteria comprising florfenicol and acetylsalicylic acid as active ingredients.

The florfenicol [2,2-dichloro-N-{1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfanyl)phenyl]ethyl}acetamide] is white or It is a pale yellowish white crystal or crystalline powder. It is difficult to dissolve in water and is well soluble in methanol.

In addition, the florfenicol is a chloramphenicol antibiotic, thiamphenicol (Dd-threo-2-dichloracetamide-1-(4-methylsulfonyl)phenyl-1,33-propanediol) It is a derivative substituted with fluorine instead of the hydroxyl group of carbon 3 of chloramphenicol and has a broad antibacterial spectrum against pathogenic bacteria including enterobacteria such as Enterobacter, Shigella, Salmonella and Escherichia coli that are resistant to chloramphenicol and thiamphenicol. It is widely used medically. In addition, florfenicol is a molecular biological improvement over chloramphenicol, and has more excellent safety for humans and animals. In addition, florfenicol exhibits antibacterial activity by inhibiting protein synthesis by directly binding to the ribosome of microorganisms.

In addition, in the present invention, the acetylsalicylic acid has a chemical formula C ₉ H ₈ O _{4 , a} melting point of 135° C., and is a white crystal with no odor. It is not well soluble in water, but is well suited to organic solvents such as alcohol, ether, and chloroform. Melts. In addition, the acetylsalicylic acid has antipyretic, analgesic, and anti-inflammatory effects, and is effective as an analgesic or a therapeutic agent for rheumatic diseases, but excessive dose causes gastric disorders. The calcium salt of this compound is well soluble in water, so it is called soluble aspirin, and is widely used in medicine.

By mixing the florfenicol and acetylsalicylic acid, it is possible to exhibit an excellent preventive and therapeutic effect against diseases caused by pathogenic bacteria to be described later than when using the florfenicol and acetylsalicylic acid, respectively.

In addition, in the present invention, the content ratio of florfenicol and acetylsalicylic acid may be 1:2 to 1:10, preferably 1:4 to 1:9, and more preferably 1:6 to 1 May be :8.

In the present invention, the pathogenic bacteria are the pathogenic bacteria Actinobacillus pleuropneumoniae ( Actinobacillus pleuropneumoniae ), Pasteurella multocida ( Pasteurella Multocida ) type A, Pasteurella multocida ( Pasteurella Multocida ) D-type and Bordetella bronchiseptica ( Bordetella bronchiseptica ) It may be one or more selected from the group consisting of.

The Actinobacilus pluropneumoniae ( Actinobacilus pleurpneumoniae ) is a causative agent of porcine pleural pneumonia with acute and chronic course, and is accompanied by fibrotic pleurisy and hemorrhagic necrotizing lesions. Respiratory diseases caused by this fungus are common in poor environments or in dense breeding conditions, and pigs infected with this disease cause growth delays including mortality and decrease in feed efficiency, which causes a lot of economic loss to the pig farming industry.

Also, the Pasteurella multocida ( Pasteurella Multocida ) is a pathogen that causes respiratory diseases in pigs as well as a fungal organism in the respiratory tract.It is classified into types A, B, D, E and F according to the serotype of the capsular membrane as Gram-negative bacteria, and toxA, which encodes a toxic protein of 145kDa. The toxicity is determined by the presence of the gene, and it tends to appear mainly in A or D type.

The Pasteurella multocida ( Pasteurella Multocida ) Type A causes bronchial pneumonia in pigs, cattle and chickens, Pasteurella multocida ( Pasteurella Multocida ) Type D is known to cause atrophic rhinitis (AR) in pigs.

In addition, the Bordetella bronchiseptica ( Bordetella bronchiseptica ) is a fungus that causes porcine atrophic rhinitis (AR) as a fungus of the porcine nasal mucosa, and symptoms of sneezing, runny nose increase, nasal congestion, dyspnea and growth sluggishness appear when swine atrophic rhinitis occurs. . After an inflammatory runny nose, nasal bleeding is also observed.

As such, the disease caused by the pathogenic bacteria may be a respiratory disease, and the respiratory disease may be a pig respiratory complex infection, pleural pneumonia, sepsis, and the like.

The veterinary composition containing florfenicol and acetylsalicylic acid according to the present invention as active ingredients can prevent and treat diseases caused by the above pathogenic bacteria.

In the present invention, the veterinary composition may further include vitamin C (Ascorbic Acid) and ferrous sulfate heptahydrate (FeSO4·7H2O).

The veterinary composition may further include vitamin C and ferrous sulfate heptahydrate (FeSO4·7H2O) to improve the preventive and therapeutic effects of the veterinary composition against diseases caused by the pathogenic bacteria, and specifically As a result, it is possible to prevent loss of appetite and slow growth rate of livestock caused by the disease caused by the pathogenic bacteria, or to accelerate the timing of overcoming them.

In the present invention, with respect to 100% by weight of the veterinary composition, the florfenicol may be 1 to 10% by weight, preferably 2 to 6% by weight, and the acetyl salicylic acid may be 10 to 50% by weight, and , Preferably it may be 20 to 40% by weight, the vitamin C may be 1 to 10% by weight, preferably 3 to 7% by weight, the ferrous sulfate heptahydrate (FeSO4 · 7H2O) May be 0.5 to 10% by weight, preferably 1 to 5% by weight, may further include an appropriate amount of an excipient to be described later, and the excipient may be powder and limestone powder.

In addition, in the present invention, the "prevention" refers to an act of improving the immunity of an animal due to the administration of the composition of the present invention so that the disease caused by the pathogenic bacteria does not occur or the degree of occurrence is reduced, and the "treatment" refers to It refers to an act of improving or beneficially altering the disease caused by the pathogenic bacteria in an animal due to the administration of the composition of the present invention, and refers to an act of eliminating clinical symptoms or alleviating the degree of occurrence. For example, the "treatment" refers to amelioration or amelioration of one or more symptoms or conditions among side effects or stress symptoms, reduction of symptom range, non-proliferation of stabilization of symptoms, suppression of symptom occurrence, delay or delay of symptom progression, symptom state Improvement or alleviation, and reduction in the occurrence of partial or total symptoms.

In addition, the veterinary composition may further contain one or more pharmaceutically acceptable carriers or diluents in addition to the mixture of the present invention when the veterinary composition is provided in the form of a pharmaceutical composition.

In addition, "pharmaceutically acceptable" in the above is physiologically acceptable, when administered to humans, does not inhibit the action of the active ingredient, and usually does not cause allergic reactions such as gastrointestinal disorders, dizziness or similar non-toxicity Refers to the composition of.

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, it may contain various drug delivery substances used for oral administration of the peptide preparation. In addition, the carrier for parenteral administration may include water, suitable oil, saline, aqueous glucose and glycol, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives are benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, etc. in addition to the above components. Other pharmaceutically acceptable carriers and formulations may be referred to as those described in the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

When the composition of the present invention is administered to a mammal, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration Can be

In addition, the veterinary composition according to the present invention may be mixed with feed and provided to livestock, and the veterinary composition may be 0.005 to 2% by weight based on the total content of the feed composition for livestock, preferably 0.01 to 1.5 It may be weight %, more preferably 0.05 to 1 weight %.

If the content of the veterinary composition is less than 0.005% by weight of the total composition for livestock feed, the prevention and treatment effect for respiratory diseases may be reduced, and if it exceeds 2% by weight, the preventive treatment effect for respiratory diseases compared to the amount added It is not economical because this is not improved, and stress can increase due to excessive drug intake when livestock eat.

In addition, the veterinary composition may further include a nutritional supplement, a digestion and absorption enhancer, a growth promoter, etc., and the feed is grain (eg, crushed or crushed wheat, oats, barley, corn, rice), vegetable Protein feed (for example, rapeseed, soybean, and sunflower-based feed), animal protein feed (for example, blood meal, meat meal, bone meal and fish meal), sugar and dairy products (for example, various milk powder and whey powder) Dry ingredients, etc.) may be further included, and may be administered to animals alone or in combination with other feeds in an edible carrier. In addition, the feed may be used as a top dressing or directly mixed with animal feeds, or It can be easily administered to animals in a separate oral formulation.

In addition, when the veterinary composition is administered separately from animal feed, it can be prepared in an immediate release or sustained release formulation by combining it with a pharmaceutically acceptable edible carrier as well known in the art. Such edible carriers may be solid or liquid, such as corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol, and when a solid carrier is used, the feed may be tablets, capsules, powders, It may be a troche or a sugar-containing tablet, or a top dressing in a non-dispersible form, and when a liquid carrier is used, the feed may be a gelatin soft capsule, or a syrup or suspension, an emulsion, or a solution formulation, but are limited thereto. no.

Hereinafter, a specific example according to the present invention will be described.

Example One

Florphenicol (ZHEJIANG KANGMU PHARMACEUTICAL.CO., LTD) 40g, acetyl salicylic acid (JQC(HUAYN) PHARMACEUTICAL.CO., LTD) 300g, vitamin C (DSM KOREA) 50g, ferrous sulfate heptahydrate (Duksan) 25g, A composition was prepared by mixing 234 g of powder (Daehan Mill) and 351 g of limestone powder (New Sinabro), and the preparation was prepared in accordance with the powder preparation method in the general formula of the animal drug process.

Example 2

Florfenicol (ZHEJIANG KANGMU PHARMACEUTICAL.CO., LTD) 40g, acetyl salicylic acid (JQC (HUAYN) PHARMACEUTICAL. It was manufactured, and the above preparation was prepared in accordance with the powder preparation method in the general formulation of the animal drug process.

Manufacturing example One

The composition prepared in Example 1 was prepared by adding 1 kg per ton of feed (No. 2, IPD) to prepare feed.

Manufacturing example 2

The composition prepared in Example 2 was prepared by adding 1 kg per ton of feed (No. 2, IPD) to prepare feed.

Experimental example

1. Materials and methods

Experiment design:

For the attack test in the laboratory, the experimental design was divided into two groups and divided into a group fed the feed prepared in Preparation Example 1 (treatment group) and a group fed the feed prepared in Preparation Example 2 (control group). .

After fasting for 3 days before feeding the feed, Pasteurella multocida type A, D type and Bordetella bronchiseptica were mixed and inoculated intranasally and feed feeding was started. After the challenge vaccination, clinical monitoring was performed for 2 weeks, blood collection and weight were measured every week, and the experimental design and treatment schedule are shown in Tables 1 and 2 below.

Disclosure money selection and specification management:

After the disclosure of 6 piglets of 4 weeks old (Dowon Farm, Jeongeup, Jeollabuk-do) with negative PRRS (Porcine Reproductive and Respiratory Syndrome virus) and major pathogens, 3 pigs were divided into treatment group and 3 pigs as control group.

Piglets in each group are stocked in two incubators for constant temperature and humidity piglets maintained at a temperature of 25°C and a humidity of 60% and fasted for 3 days before feeding the feeds prepared in Preparation Examples 1 and 2, and then feed the feed. During the breeding period, water was supplied unlimitedly.

Attack vaccination:

A major cause of respiratory acute and chronic respiratory distress, coughing and atrophic rhinitis bacteria wave stew Pasteurella far Toshio the (Pasteurella multocida ) type A, type D, and Bordetella bronchiseptica were collected from piglets with respiratory symptoms requested by Chonbuk National University Animal Disease Diagnosis Center.

Piglets in the treatment group and the control group were inoculated with 0.5 ml of azaperon (StressGuard) to induce muscle relaxation and sedation, and then Pasteurella multocida types A, D and Bordetella bronchiseptica ( Bordetella bronchiseptica ) was cultured at a titer of 1× ^{10 9} CFU (Colony Forming Unit)/ml, and the mixed inoculum was inoculated with a total of 2 ml each in each nasal cavity using a nasal sprayer.

2. Sample collection and investigation items and methods

Blood and nasal cavity Swap Picking:

Blood collection and serum separation were performed at 28 days of age (before attack vaccination), 31 days of age (attack vaccination day), 38 days of age (after attack vaccination 1 week), and 45 days of age (after 2 weeks of attack vaccination), and the time of experiment by collecting nasal swabs Until stored at -80°C.

Observation of clinical symptoms:

According to the clinical score criteria in Table 3 below, the clinical symptoms of Gongsi pigs are 28 days old (before attack vaccination), 31 days old (at attack vaccination day), 38 days old (after 1 week after attack vaccination), 45 days old (2 weeks after attack vaccination). After), the body temperature, gait, coat condition, mortality, etc. of Gongsidon were measured and compared, and the results are shown in FIG. 1.

Statistical analysis of clinical symptom scores for each group was performed using the Mann-whitney method to determine the significance.

Analysis of daily weight gain related to productivity:

At 28 days of age (before attack vaccination), 31 days of age (attack vaccination day), 38 days of age (after 1 week of attack vaccination), and 45 days of age (after 2 weeks of attack vaccination), the weight of the donors was measured, and the daily gain was analyzed. The results are shown in FIG. 2.

Statistical analysis of daily weight gain for each group was checked for significance using the Mann-whitney method.

Measurement of the number of bacteria in the nasal cavity and tissues:

The nasal and tissue swabs of piglets in the control and treatment groups were performed. The swab sample was immediately transported to the laboratory in a container containing the medium immediately after collection. Swap samples were stored at -80°C. Selected Samples were diluted in phosphate buffer saline (PBS, Phosphate buffer saline) in stages and 200 in blood medium (Tryptic Soy Agar, Sigma-Aldrich containing 5% sheep blood) containing 5% sheep blood. smeared by ㎕ and specificity of the colonies formed by the culturing for a day at 37 ℃ of wave stew Pasteurella far Toshio the (Pasteurella Multocida) A-type, wave stew Pasteurella far Toshio the (Pasteurella Multocida ) D-type or Bordetella bronchiseptica ( Bordetella bronchiseptica ) was calculated by measuring the number of colonies, and the results are shown in FIGS. 3 and 4.

The number of detected bacteria by group was checked for significance using the Mann-whitney method.

Histopathologic inspection

1) Pathological tissue sample

An autopsy is performed at 45 days of age, 2 weeks after the vaccination of the attack, and the gross findings of each organ are recorded (the results of the autopsy), and the lungs, tonsils, pulmonary lymph nodes, mesenteric lymph nodes, and mandibular lymph nodes, etc. The main organs were fixed in 10% formalin.

2) Histopathological observation and analysis method

Tissues fixed in formalin are subjected to hematoxylin & eosin staining through an embedding process. Organs stained with H&E were observed under a microscope, and the lesion was measured according to the following measurement method, and the results are shown in FIGS. 5 to 10.

(1) The pneumonia score was evaluated by visual and palpation, and the lesions of each lung lobe were left/right apical lobes and left/right cardiac lobes according to the estimated volume ratio of Pointonet al (1999). , Intermediate lobes each have a weight of 10%, and left and right diaphragmatic lobes each have 25%, and the characteristic red-purple area of epidemic pneumonia over the entire lung is converted to a percent. Record the pneumonia index.

-0: 0%

-1: 1-10%

-2: 11-20%

-3: 21-30%

-4: 31~40%

-5: 41% or more

(2) In the case of atrophic rhnitis, the degree of loss of the nasal septum and turbinate that can be observed by cutting between the 1st and 2nd progenitors was evaluated according to the criteria in Table 4 below, and an index of 0-5.

Statistical Analysis:

In the case of a continuous variable, a repeated measure of ANOVA is used to reject or adopt the null hypothesis through the difference in the mean of each group, or a Student's T test is performed for timely comparison. If it is judged that the normal distribution of the population cannot be defined because a large number of animals cannot be used due to the nature of the experiment requiring SPF piglets, the Mann-Whitney U test or the Wilcoxon signed-rank test is performed. For non-continuous variables, Chi-square test is performed for comparison between two groups.

3. Experiment result

1) clinical symptoms

Referring to FIG. 1, there were no conspicuous clinical symptoms other than that the coat of some piglets in the treatment group became slightly rough, but clinical symptoms such as lethargy and respiratory symptoms were observed in the control group from 7 days after the challenge vaccination.

2) Weight gain Analysis

Referring to FIG. 2, the average daily gain of the treatment group was 0.16 kg, which was lower than the average daily gain of the control group (0.32), but no statistical significance was observed.

3) Results of measuring the number of bacteria in the nasal cavity and tissues

Referring to FIG. 3, the average number of colonies of Pasteurella multocida in the nasal cavity of the control group and the treatment group on the 7th day of challenge inoculation were 1.51×10 ⁴ CFU/ml and 9.67×10 ³ CFU/ml, and attack inoculation 14 The average number of colonies of Pasteurella multocida in the airways of the control group and treatment group on the day were 7.50×10 ¹ CFU/ml and 1.67×10 ¹ CFU/ml. In addition, the number of colonies of Pasteurella multosada bacteria in lung tissue at 14 days of challenge vaccination was observed only in the control group (4.17×10 ¹ CFU/ml).

At all times, the number of colonies of Pasteurella multocida by each tissue was significantly higher in the control group than in the treatment group.

Referring to FIG. 4, the number of colonies of Bordetella bronchiseptica was detected only in the nasal cavity of the control group and the treatment group on the 7th day of the challenge inoculation, and was not observed in the tissue on the 14th day of the challenge inoculation. In addition, the average number of colonies of Bordetella bronchiseptica bacteria in the nasal cavity of the control group was 1.00×10 ³ CFU/ml, which was higher than that of the treatment group (5.00×10 ² CFU/ml), and there was no significance between groups.

4) Histopathologic test results

5 and 6, a red-violet region was observed at the corners of each lung lobe of the control group, and it can be seen that the lungs are swollen. In particular, the left diaphragm lobe and the corners of the heart lobe of one piglet of the control group are red-purple due to bacterial infection. It can be seen that it has changed.

On the other hand, referring to FIG. 7, in the treatment group, the lungs were overall pink and showed normal autopsy findings. Referring to FIG. 8, the pneumonia index was also the same as the autopsy findings in the control group (26.67%) than in the treatment group (1.67%). It was a significantly higher level.

In addition, referring to Figure 9, as a result of observing the nasal septum and the turbinate, it was confirmed that the treatment group had no lesions similar to that of normal pigs, and the control group observed an irregular shape of the turbinate, and some turbinate tissue was damaged, so that the structure of the nasal cavity was wide. 10, it can be seen that the atrophic rhinitis index was higher in the control group (mean index: 2) than the treatment group (mean index: 1.3).

Referring to the results of the experimental example, the treatment group showed statistically significant lower levels of clinical symptoms and pathological lesions (pneumonia and atrophic rhinitis) compared to the control group.

In addition, in the nasal cavity and tissues of the treatment group, the number of colonies of Pasteurella multocida and Bordetella bronchiseptica was lower than that of the control group, so that the veterinary composition according to the present invention has higher antimicrobial and It can be seen that it has an anti-inflammatory effect.

In addition, in the group treated with the veterinary composition according to the present invention, it can be seen that there is no problem in safety as no specific side effects were observed compared to the control drug fed group.

Thus, in the case of the veterinary composition according to the present invention, by mixing florfenicol and acetyl salicylic acid, it is possible to prevent and treat diseases caused by pathogenic bacteria, thereby providing a veterinary composition capable of preventing a decrease in the production of livestock. You will be able to.

Claims (5)

delete delete delete With respect to 100% by weight of the veterinary composition, Florfenicol (Florfenicol) 2 to 6% by weight, acetylsalicylic acid (Acetylsalicylic Acid) 20 to 40% by weight, and vitamin C (Ascorbic Acid) 3 to 7% by weight, including, Pasteur Pasteurella far Toshio the (Pasteurella Multocida) a-type, wave stew Pasteurella far Toshio the (Pasteurella Multocida) D-type and Bordetella chevron kisep urticae (Bordetella bronchiseptica) pathogenic composite swine respiratory complex infection by infection of bacteria containing (PRDC , Porcine respiratory disease complex) prevention and treatment of a veterinary composition. The method of claim 4,
The veterinary composition is a veterinary composition, characterized in that 0.005 to 2% by weight based on the total content of the feed composition for livestock.

Images